Lenalidomide, a derivative of thalidomide, has emerged as a groundbreaking drug in modern oncology, particularly for patients battling multiple myeloma and certain types of lymphoma. As an immunomodulatory agent, Lenalidomide not only targets cancer cells directly but also enhances the body's natural defense mechanisms. Over the past decade, its use has significantly improved survival rates,...